Not Cleared Post-NSE

DEN040011 - AMPLICHIP CYP450 TEST, MODEL 04381866190

DEN040011 is an FDA 510(k) submission for AMPLICHIP CYP450 TEST, manufactured by Roche Molecular Systems, Inc.. The device is a Class 2 Chemistry device with product code NTI cleared through the Post-NSE 510(k) pathway after a 3-day FDA review.

DEN040011 · Roche Molecular Systems, Inc. · Chemistry device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Dec 2004
Decision
3d
Days
Class 2
Risk

DEN040011 is an FDA 510(k) submission (not cleared) for the AMPLICHIP CYP450 TEST, MODEL 04381866190. Classified as Drug Metabolizing Enzyme Genotyping Systems (product code NTI), Class II - Special Controls.

Submitted by Roche Molecular Systems, Inc. (Pleasanton, US). The FDA issued a Not Cleared (DENG) decision on December 23, 2004 after a review of 3 days.

This device falls under the Chemistry FDA review panel, regulated under 21 CFR 862.3360 - the FDA in vitro diagnostics and chemistry framework. The Traditional 510(k) pathway requires demonstration of substantial equivalence to a legally marketed predicate device - a standard the FDA determined was not met in this submission.

Device pattern: High-complexity regulatory submission. Elevated predicate reliance profile. This submission did not achieve clearance, indicating the FDA determined the device lacked sufficient predicate equivalence under the Chemistry review framework.

FDA 510(k) Submission Details - DEN040011

510(k) Number DEN040011 FDA.gov
FDA Decision Not Cleared Not Substantially Equivalent (DENG)
Date Received December 20, 2004
Decision Date December 23, 2004
Days to Decision 3 days
Submission Type Post-NSE
Review Panel Chemistry (CH)
Summary -
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
86d faster than avg
Panel avg: 89d · This submission: 3d
Pathway characteristics

NTI Device Classification - Class 2, Special Controls

Product Code NTI Drug Metabolizing Enzyme Genotyping Systems
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 862.3360
Definition Intended To Identify The Presence Or Absence Of Human Genotypic Markers Encoding Drug Metaboizing Enzymes Using Dna Originating From Clinical Samples. This Type Of Assay Can Be Used As An Aid Determining Treatment Choice And Individualizing Treatment Dose For Therapeutics That Are Metabolized Primarily By The Specific Enzyme Tested By The System.
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Chemistry devices follow this clearance model.

Regulatory Peers - NTI Drug Metabolizing Enzyme Genotyping Systems

All 10
Devices cleared under the same product code (NTI) and FDA review panel - the closest regulatory comparables to DEN040011.
XTAG CYP2D6 KIT V3, MODEL I030C0300 (96 TESTS/KIT), TDAS CYP2D6 SOFTWARE (2030-0254)
K093420 · Luminex Molecular Diagnostics, Inc. · Aug 2010
INVADER UGT1A1 MOLECULAR ASSAY
K051824 · Third Wave Technologies, Inc. · Aug 2005
ROCHE AMPLICHIP CYP450 TEST
K043576 · Roche Molecular Systems, Inc. · Jan 2005
DEN040011 · AMPLICHIP CYP450 TEST, MODEL 04381866190
Download PDF Roche Molecular Syste…